IntroductionSulphonylureas have been used for over 50 years to enhance insulin secretion in patients with Type II (non-insulin-dependent) diabetes mellitus but their therapeutic target was not discovered until 1985 and we are only just beginning to address their molecular mechanism of action. The sulphonylurea drugs were discovered serendipitously by Marcel Janbon in 1942, when he observed a high incidence of hypoglycaemic symptoms in typhoid patients treated with the bacteriostatic agent p-aminobenzenesulphamidoisopropylthiodiazole (2254RP) [1]. This observation was extended by Auguste Loubatires, who showed that 2254RP induced hypoglycaemia in dogs by stimulating insulin secretion [2]. Subsequently, it was discovered that another sulphonamide drug being tested for bacteriostatic effects, carbutamide, also caused hypoglycaemia in man [3]. Clinical studies followed and led to the development of tolbutamide for the treatment of Type II diabetes. The full story of these pioneering experiments has been vividly recounted in an earlier review by Henquin [4]. Numerous sulphonylureas and related compounds have now been synthesized, with different potencies and time-courses of action and many millions of Type II diabetic patients are now routinely treated with these drugs.The first clues to the mechanism of action of sulphonylureas on insulin secretion came with the discovery that these drugs depolarize the pancreatic beta cell and stimulate electrical activity [5] and the finding that this depolarization was due to a decrease in the potassium permeability of the beta-cell membrane [6]. Patch-clamp studies subsequently showed that sulphonylureas interact specifically with the ATP-sensitive potassium (K ATP ) channel in the betacell membrane and bring about its closure [7]. The activity of the K ATP channel sets the resting membrane potential of the unstimulated beta cell and its closure decreases the membrane K + permeability, producing membrane depolarization and insulin secretion [8]. Radioligand binding studies established the presence of both low-affinity and high-affinity sulphonylurea binding sites in the beta-cell membrane [9, 10] and led to considerable speculation about whether the high-affinity sulphonylurea receptor and the K ATP channel were the same or different proteins. The purification and subsequent cloning of a high-affinity sulphonylurea receptor from insulinoma cells [11] resolved this issue by showing that this receptor is an integral component of the K ATP channel [12,13].In this article, we review the role of the K ATP channel in insulin secretion in health and disease. We also summarise current knowledge of how sulphonylureas act on the different types of K ATP channel found in beta cells and in extra-pancreatic tissues, and discuss the implications of these findings for the use of sulphonylureas as therapeutic agents to stimulate insulin secretion in humans. Finally, we consider the evidence for additional targets for sulphonylureas, both within the beta cell and in extra-pancreatic tissues.Funct...